English This Activity for
- Resident / Fellow
- Physician
What I will learn?
In this webinar, key experts in the field from Europe and China, will discuss the importance of CRP levels in predicting treatment response in active axSpA. It is widely believed that CRP levels are always elevated in these patients; however, up to 59% of patients with active axSpA may have normal CRP, and the disease burden is independent of baseline CRP in active axSpA.
We will review how CRP levels are a good predictor of response to TNFi or IL-17i in axSpA patients, using guidelines, RCT data, and clinical experience as the evidence and support.
Lastly, a clinical case will be showcased, and you will have the opportunity to discuss live or ask any questions you may have to our panel of experts.
We will review how CRP levels are a good predictor of response to TNFi or IL-17i in axSpA patients, using guidelines, RCT data, and clinical experience as the evidence and support.
Lastly, a clinical case will be showcased, and you will have the opportunity to discuss live or ask any questions you may have to our panel of experts.
Additional items to the activity
| Optional Details | Type | Fee |
|---|---|---|
|
Taltz® in active axSpA – Proven efficacy in normal and elevated CRP levels Certificate
Certificate |
Certificate | Free |
VAT 15% Included
